Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer
OBJECTIVES: I. Determine the effects on 2 year progression-free survival of a regimen
consisting of cyclophosphamide, paclitaxel, and filgrastim (G-CSF) to mobilize peripheral
blood progenitor cells (PBPCs), followed by 2 courses of carboplatin and paclitaxel followed
by 1 course of melphalan, each supported with PBPCs and G-CSF, in patients with recurrent or
refractory, advanced breast cancer. II. Evaluate the feasibility of administering multiple
courses of high dose chemotherapy in an outpatient setting for these patients. III. Evaluate
the rate of complete response to the high dose therapy in these patients.
OUTLINE: This is a multicenter study. Patients receive mobilization therapy consisting of
cyclophosphamide IV over 1 hour followed by paclitaxel IV over 3 hours, then filgrastim
(G-CSF) beginning 24 hours following completion of paclitaxel and continuing through the
last day of leukapheresis. Leukapheresis continues until an adequate number of CD34+ cells
is collected. Following cell count recovery, patients receive 3 courses of high-dose
chemotherapy: 2 courses of paclitaxel IV over 3 hours followed by carboplatin IV over 1
hour, with the first course generally within 21 days after completion of leukapheresis and
the second course 21-35 days after the first; then 1 course of melphalan IV infused over 30
minutes 21-35 days after the previous carboplatin dose. Each course of chemotherapy is
followed 24-48 hours later by the infusion of G-CSF-mobilized peripheral blood progenitor
cells and G-CSF. Patients are followed every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 96 evaluable patients will be accrued for this study over 3
years.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Thomas C. Shea, MD
Study Chair
UNC Lineberger Comprehensive Cancer Center
United States: Institutional Review Board
LCCC 9727
NCT00003392
September 1997
January 2003
Name | Location |
---|---|
Walter Reed Army Medical Center | Washington, District of Columbia 20307-5000 |
University of Chicago Cancer Research Center | Chicago, Illinois 60637 |
Lineberger Comprehensive Cancer Center, UNC | Chapel Hill, North Carolina 27599-7295 |
University of Pennsylvania Cancer Center | Philadelphia, Pennsylvania 19104 |
Temple University Cancer Center | Philadelphia, Pennsylvania 19140 |
Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |
Lutheran General Cancer Care Center | Park Ridge, Illinois 60068 |
New York Medical College | Valhalla, New York 10595 |
Scripps Clinic | La Jolla, California 92037 |
Methodist Hospital-Central Unit | Memphis, Tennessee 38104 |
University of California San Diego | La Jolla, California 92093 |
Bone Marrow Stem Cell Transplant Institute of Florida | Fort Lauderdale, Florida 33313 |
Stem Cell Sciences | New York, New York 10016 |
University of Rochester School of Medicine | Rochester, New York 14642 |